ALNYLAM PHARMACEUTICALS, INC. (ALNY) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-02-12

Key Insights

Alnylam Pharmaceuticals reported its Q4 2025 financial results, indicating the company's continued growth and strong performance.
The company did not disclose any material agreements, leadership changes, or other significant events that would be considered a major event.
Based on the information provided, there are no major red flags or concerns that would significantly impact the company's outlook or investor sentiment.

Want the newest filings?

This analysis covers the filing from 2026-02-12. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-12

Alnylam Pharmaceuticals announced its new five-year strategy, 'Alnylam 2030', indicating a long-term focus on growth and innovation.
The company reported preliminary Q4 2025 and full-year 2025 global net product revenues of approximately $995 million and $2,987 million, respectively, for its key products AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
Alnylam provided its 2026 product and pipeline goals, as well as full-year 2026 combined net product revenue guidance, suggesting confidence in future performance.

Other reports for ALNYLAM PHARMACEUTICALS, INC.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.